Imviva Biotech received an FDA investigational device exemption (IDE) to use Adaptive Bio-Technologies’ ClonoSeq MRD assay in its TENACITY-01 Phase Ib/II trial of CTD402, an allogeneic anti-CD7 CAR T-cell therapy for T-ALL/T-LBL and MRD-positive remission settings. ClonoSeq will support patient selection using an MRD threshold of 0.1% and quantify MRD for exploratory post-treatment analyses.